Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial von Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W

Volltext

Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making von Stebbing, Justin, Singh Wasan, Harpreet

Volltext

Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply von Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W

Volltext

Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study von Primrose, John Neil, Fox, Richard, Palmer, Daniel H., Prasad, Raj, Mirza, Darius, Anthoney, David Alan, Corrie, Philippa, Falk, Stephen, Wasan, Harpreet Singh, Ross, Paul J., Wall, Lucy R., Wadsley, Jonathan, Evans, T.R. Jeffry, Stocken, Deborah, Praseedom, Raaj, Cunningham, David, Garden, O James, Stubbs, Clive, Valle, Juan W., Bridgewater, John A.

Volltext

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial von Kopetz, Scott, Murphy, Danielle A., Pu, Jie, Ciardiello, Fortunato, Desai, Jayesh, Van Cutsem, Eric, Wasan, Harpreet Singh, Yoshino, Takayuki, Saffari, Hedieh, Zhang, Xiaosong, Hamilton, Phineas, Xie, Tao, Yaeger, Rona, Tabernero, Josep

Volltext

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial von Kopetz, Scott, Yoshino, Takayuki, Van Cutsem, Eric, Eng, Cathy, Kim, Tae Won, Wasan, Harpreet Singh, Desai, Jayesh, Ciardiello, Fortunato, Yaeger, Rona, Maughan, Timothy S, Beyzarov, Elena, Zhang, Xiaoxi, Ferrier, Graham, Zhang, Xiaosong, Tabernero, Josep

Volltext

BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-o... von Kopetz, Scott, Yoshino, Takayuki, Kim, Tae Won, Wasan, Harpreet Singh, Van Cutsem, Eric, Ciardiello, Fortunato, Maughan, Timothy S., Eng, Cathy, Yaeger, Rona, Desai, Jayesh, Zhang, Xiaosong, Usari, Tiziana, Mori, Ave, Tabernero, Josep

Volltext

A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers von Pant, Shubham, Ducreux, Michel, Harding, James J., Javle, Milind M., Oh, Do-Youn, Wasan, Harpreet Singh, Fortenberry, Allison, Josephson, Neil C., Mwatha, Anthony, Wang, Kui, Fan, Jia

Volltext

Zanidatamab (zani) in previously treated HER2+ biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study von Pant, Shubham, Fan, Jia, Oh, Do-Youn, Choi, Hye Jin, Kim, Jin Won, Chang, Heung-Moon, Bao, Lequn, Sun, Hui-Chuan, Macarulla, Teresa, Xie, Feng, Metges, Jean-Philippe, Ying, Jie-Er, Bridgewater, John A, Tejani, Mohamedtaki Abdulaziz, Chen, Emerson Yu-sheng, Wasan, Harpreet Singh, Ducreux, Michel Pierre, Ma, Jiafang, Garfin, Phillip M., Harding, James J.

Volltext

BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant ( BRAF V600E ) metastatic colorectal cancer (mC... von Kopetz, Scott, Yoshino, Takayuki, Kim, Tae Won, Desai, Jayesh, Yaeger, Rona, Van Cutsem, Eric, Ciardiello, Fortunato, Wasan, Harpreet Singh, Maughan, Tim, Zhang, Yuanyuan, Usari, Tiziana, Chung, Chin-Hee, Zhang, Xiaosong, Tabernero, Josep

Volltext

Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study von Kopetz, Scott, Murphy, Danielle A., Pu, Jie, Yaeger, Rona, Ciardiello, Fortunato, Desai, Jayesh, Van Cutsem, Eric, Wasan, Harpreet Singh, Yoshino, Takayuki, Elez, Elena, Golden, Adele, Zhu, Zhou, Zhang, Xiaosong, Tabernero, Josep

Volltext

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal canc... von Kopetz, Scott, Grothey, Axel, Yaeger, Rona, Ciardiello, Fortunato, Desai, Jayesh, Kim, Tae Won, Maughan, Tim, Van Cutsem, Eric, Wasan, Harpreet Singh, Yoshino, Takayuki, Edwards, Michelle L., Golden, Adele, Gollerkeri, Ashwin, Tabernero, Josep

Volltext

ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem) von McNamara, Mairead Geraldine, Timmins, Hayley, Osborne, Ashley, Cox, Rebecca, Wasan, Harpreet Singh, Corrie, Pippa, Gillmore, Roopinder, Sivakumar, Shivan, Ma, Yuk Ting, Faluyi, Olusola Olusesan, Arora, Arvind, Arif, Seema, Canham, Jo, Hurt, Chris, Hubner, Richard, Bridgewater, John A, Adams, Richard, Valle, Juan W.

Volltext

Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC) von Pant, Shubham, Fan, Jia, Oh, Do-Youn, Choi, Hye Jin, Kim, Jin Won, Chang, Heung-Moon, Bao, Lequn, Sun, Hui-Chuan, Macarulla Mercade, Teresa, Xie, Feng, Metges, Jean Philippe, Jieer, Ying, Bridgewater, John A, Tejani, Mohamedtaki Abdulaziz, Chen, Emerson Yu-sheng, Wasan, Harpreet Singh, Ducreux, Michel Pierre, Ma, Jia-Fang, Garfin, Phillip M., Harding, James J.

Volltext

Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/... von Lamarca, Angela, Palmer, Daniel H., Wasan, Harpreet Singh, Ross, Paul J., Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Hobbs, Claire, Wilkinson, Lorna, Macdonald, Timothy, Hartley, Claire, Ryder, David, Bridgewater, John A., Valle, Juan W.

Volltext

BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAF V600E metastatic colorectal cancer (mCRC) von Kopetz, Scott, Yoshino, Takayuki, Kim, Tae Won, Yaeger, Rona, Desai, Jayesh, Wasan, Harpreet Singh, Van Cutsem, Eric, Ciardiello, Fortunato, Maughan, Tim, Eng, Cathy, Tie, Jeanne, Elez, Elena, Lonardi, Sara, Zhang, Xiaosong, Chung, Chin-Hee, Usari, Tiziana, Nicholz, Tim, Murphy, Danielle A., Tabernero, Josep

Volltext

Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) von Kopetz, Scott, Aderka, Dan, Grothey, Axel, Van Cutsem, Eric, Yaeger, Rona, Wasan, Harpreet Singh, Yoshino, Takayuki, Desai, Jayesh, Ciardiello, Fortunato, Gollerkeri, Ashwin, Golden, Adele, Edwards, Michelle L., Tabernero, Josep

Volltext

Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study von Kopetz, Scott, Murphy, Danielle A., Pu, Jie, Ciardiello, Fortunato, Desai, Jayesh, Grothey, Axel, Van Cutsem, Eric, Wasan, Harpreet Singh, Yaeger, Rona, Yoshino, Takayuki, Donahue, Amber C, Golden, Adele, Gollerkeri, Ashwin, Zhu, Zhou, Tabernero, Josep

Volltext

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant ( BRAF V600E ) metastatic colo... von Kopetz, Scott, Grothey, Axel, Yaeger, Rona, Ciardiello, Fortunato, Desai, Jayesh, Kim, Tae Won, Maughan, Tim, Van Cutsem, Eric, Wasan, Harpreet Singh, Yoshino, Takayuki, Edwards, Michelle L., Golden, Adele, Gollerkeri, Ashwin, Tabernero, Josep

Volltext

Global BRAF testing practices in metastatic colorectal cancer (mCRC) von Desai, Jayesh, Kopetz, Scott, Grothey, Axel, Ciardiello, Fortunato, Kim, Tae Won, Maughan, Tim, Van Cutsem, Eric, Wasan, Harpreet Singh, Yaeger, Rona, Yoshino, Takayuki, Gollerkeri, Ashwin, Edwards, Michelle L., Rodriguez Lizaso, Montessa, Tabernero, Josep

Volltext